Announcement PDF ASX Release AusIndustry Awards Recce Support for AU$5.6m of Technically Advanced Overseas Drug Development SYDNEY Australia, 15 January 2018: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), developing a new class of synthetic antibiotics, today announced that it has been awarded an Advanced Finding upon AU$5.6 million of overseas drug development from AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science. The substantial 43.5% rebate applicable to Australian Research and Development, is now awarded to Recce to include its overseas advanced drug development for the financial year ending June 2017 and through the following two financial years to mid-2019. The funds include and cover some expenditure already undertaken and apply to all antibiotics under development according to: Development Pilot plant and development testing Toxicology studies Efficacy studies Pharmacology studies Analytical methods Value ($) $2,887,105 $1,278,532 $456,668 $109,021 $874,383 The reassurance of the Australian Government’s commitment to reimburse Recce for its local and now international drug development activities, works to reinforce the Company’s focus on the United States as a major component of the world pharmaceutical market. The reimbursement of developmental funds will greatly support Recce’s present FDA activities and anticipated human clinical trials. Dr Graham Melrose, Recce’s Executive Chairman, said: “The Australian life sciences sector is booming. With companies listed on the ASX combined market capitalisation of more than AU$80 billion1, it continues to be a significant economic driver for our country. We thank the Australian Government for awards such as this, which encourage innovation and development within the sector.” About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results to date. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-man clinical trials. 1 - https://www.mtpconnect.org.au/Category?Action=View&Category_id=87 For further information please visit www.recce.com.au or contact: Investor Relations James Graham Executive Director Recce Pharmaceuticals Ltd Tel: +61 (02) 8075 4585 Media (Australia) Andrew Geddes CityPR Tel: +61 (02) 9267 4511 Media (International) Sue Charles/Gemma Harris Instinctif Partners Tel: +44 (0)20 7866 7860 E: recce@instinctif.com